Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity

Fig. 2

HuB6 has high binding specificity and affinity. a HuB6 bound to both the monomeric form (mono-Hu4-1BB) and dimeric form (Hu4-1BB-mFc WT) of human 4-1BB, as determined by ELISA. b The dynamic curves for HuB6, utomilumab and urelumab binding to cynomolgus monkey 4-1BB (Cy4-1BB) determined by ELISA. c The dynamic curves for HuB6, utomilumab and urelumab binding to murine 4-1BB (Mu4-1BB) determined by ELISA. d The fluorescence values of activated CD8 + T cells binding with FITC-labeled HuB6, utomilumab or an isotype antibody determined by flow cytometry. The results are representative of three different experiments and expressed as the mean value ± SD. **p < 0.001 compared to the utomilumab group. *p < 0.001 compared to the IgG group. e HuB6 binding selectivity to TNFRSF members including 4-1BB, OX40, CD40 and CD27 was evaluated using flow cytometry and ELISA

Back to article page